Cord Dohrmann - Evotec SE Executive
| EVOTF Stock | USD 6.77 0.00 0.00% |
Executive
Dr. Cord Dohrmann has served as Chief Scientific Officer and Member of the Management Board at Evotec AG since September 1, 2010. Dr. Dohrmann has spent over 20 years in biomedical research at academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tuebingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the MaxPlanck Institute in Tuebingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a startup to an internationally recognized metabolic disease company with a pipeline of innovative preclinical and clinical products for the treatment of diabetes and related disorders since 2010.
| Age | 59 |
| Tenure | 14 years |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Esq III | Pacira BioSciences, | 50 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Craig MD | Alkermes Plc | 56 | |
| Samuel Parisi | Alkermes Plc | 49 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Glenn David | Phibro Animal Health | 52 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
| David Boyer | Neurocrine Biosciences | 45 | |
| DO Ellis | Pacira BioSciences, | 53 | |
| David Ng | HUTCHMED DRC | N/A | |
| Richard Kahr | Pacira BioSciences, | N/A | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Christine CPA | Prestige Brand Holdings | 48 | |
| Angie Woods | Avadel Pharmaceuticals PLC | N/A | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 |
Evotec SE Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | ||
| Volker Braun, VP ESG | ||
| Cord Dohrmann, Chief Scientific Officer and Member of Management Board | ||
| Enno Spillner, CFO, Member of the Management Board | ||
| Monika Conradt, Global HR | ||
| Gabriele Hansen, Vice President Corporate Communications & Investor Relations | ||
| Christian Dargel, EVP Compliance | ||
| MBA MBA, Chairman CEO | ||
| Craig Johnstone, COO, Member of the Management Board | ||
| Anja Bosler, Principal Accounting |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 176.95 M | |||
| Shares Owned By Insiders | 9.86 % | |||
| Shares Owned By Institutions | 66.12 % | |||
| Price To Earning | 347.66 X | |||
| Price To Book | 2.28 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Evotec Pink Sheet
Evotec SE financial ratios help investors to determine whether Evotec Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evotec with respect to the benefits of owning Evotec SE security.